A preclinical study regarding a novel oncolytic adenovirus carrying a SIRPα–IgG1 Fc fusion gene (termed SG635-SF) showed that SIRPα-Fc fusion protein enhances the anti-tumor effect of oncolytic adenovirus against ovarian cancer [27]. This evidence concerns the gene SIRPA and ovarian cancer.